Reparixin L-lysine salt
Based on 63 publication(s) in Google Scholar
Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 266359-93-7
- Formula: C20H35N3O5S
- Molecular Weight:429.57
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Reparixin L-lysine salt
More- Cancer Cell. 2023 Apr 10;41(4):693-710.e8. [Abstract]
- Science. 2026 Mar 26;391(6792):eadz9353. [Abstract]
- Ann Rheum Dis. 2016 Apr;75(4):721-9. [Abstract]
- Ann Rheum Dis. 2016 Apr;75(4):730-8. [Abstract]
- Nat Commun. 2017 May 26:8:15584. [Abstract]
- J Biomed Sci. 2025 Jan 6;32(1):5. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(11):e2406218. [Abstract]
- Adv Sci (Weinh). 2024 Sep 13:e2403430. [Abstract]
- Sci Adv. 2019 May 8;5(5):eaav7384. [Abstract]
- Mol Biomed. 2025 Jun 10;6(1):40. [Abstract]
- Cell Death Dis. 2017 Jul 13;8(7):e2932. [Abstract]
- Cancer Lett. 2026 May 1:645:218395. [Abstract]
- J Allergy Clin Immunol. 2018 Jun;141(6):2286-2289.e5. [Abstract]
- Cell Commun Signal. 2023 Mar 13;21(1):59. [Abstract]
- Mol Ther. 2022 Nov 2;30(11):3430-3449. [Abstract]
- EBioMedicine. 2019 May:43:487-500. [Abstract]
- Dev Cell. 2026 Jan 12:S1534-5807(25)00768-3. [Abstract]
- BMC Med. 2022 Feb 8;20(1):55. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2024;18(2):101351. [Abstract]
- Front Immunol. 2022 Oct 17:13:1007341. [Abstract]
- Cancer Cell Int. 2021 Jul 3;21(1):337. [Abstract]
- Front Immunol. 2021 May 7:12:667177. [Abstract]
- Front Immunol. 2018 Sep 12:9:2058. [Abstract]
- Cell Biosci. 2019 Jan 3:9:4. [Abstract]
- Int Endod J. 2026 Jun 24. [Abstract]
- Cells. 2026 Feb 3;15(3):289. [Abstract]
- J Mol Cell Biol. 2023 Aug 3;15(4):mjad025. [Abstract]
- Cells. 2022 Aug 4;11(15):2402. [Abstract]
- Cells. 2022 Jun 21;11(13):1986. [Abstract]
- Neurobiol Dis. 2021 Dec:160:105538. [Abstract]
- Oncogenesis. 2016 Jun 13;5(6):e234. [Abstract]
- Brain Pathol. 2025 Jan;35(1):e13283. [Abstract]
- J Mol Med (Berl). 2019 Jan;97(1):25-35. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):220-230. [Abstract]
- Sci Rep. 2017 Nov 6;7(1):14510. [Abstract]
- Cancers (Basel). 2023 Sep 4;15(17):4422. [Abstract]
- Stem Cells. 2015 Dec;33(12):3558-68. [Abstract]
- J Cell Mol Med. 2020 Nov;24(21):12608-12618. [Abstract]
- J Cell Mol Med. 2020 Jan;24(2):1588-1598. [Abstract]
- Brain Res Bull. 2025 Nov:232:111594. [Abstract]
- J Immunol. 2018 Jul 15;201(2):814-820. [Abstract]
- Xenotransplantation. 2018 Mar;25(2):e12385. [Abstract]
- Mol Immunol. 2018 Sep:101:440-449. [Abstract]
- J Gastroenterol Hepatol. 2018 Feb;33(2):431-442. [Abstract]
- Biomed Res Int. 2020 Aug 5:2020:4670604. [Abstract]
- FACETS. 2020 Jul.
- Gene. 2018 Nov 30:677:149-162. [Abstract]
- Vet Immunol Immunopathol. 2016 Dec:182:52-58. [Abstract]
- bioRxiv. 2025 Sep 3:2025.09.02.672566. [Abstract]
- bioRxiv. 2025 Mar 19:2025.03.19.644113. [Abstract]
- Patent. US20240295544A1.
- bioRxiv. 2024 Jun 6:2024.01.30.577927. [Abstract]
- Patent. US20220251222A1.
- Karolinska Institutet. 2022 Feb.
- Int J Biol Sci. 2022 Jan 16;18(4):1363-1380. [Abstract]
- Research Square Preprint. 2021 Mar.
- bioRxiv. 2020 Sep 12:2020.08.25.265561. [Abstract]
- University of Michigan. 2018 Oct.
- Oncotarget. 2018 Aug 24;9(66):32556-32569. [Abstract]
- Oncotarget. 2017 Jul 21;8(36):60210-60222. [Abstract]
- Patent. US20170181987A1.
- Patent. US20170105971A1.
- Johns Hopkins University. 2016 Dec.
Customer Validation & Images
-
IF
-
Cell Proliferation/Viability Assay
-
IF
-
Cell Proliferation/Viability Assay
Biological Activity
|
CXCR1wt 5.6 nM (IC50, in L1.2 cells) |
CXCR1Ile43Val 80 nM (IC50, in L1.2 cells) |
CXCR1 1 nM (IC50, in cells) |
CXCR2 ∼100 nM (IC50, in cells) |
Reparixin is a potent functional inhibitor of CXCL8-induced biological activities on human PMNs with a marked selectivity (around 400-fold) for CXCR1, as shown in specific experiments on CXCR1/L1.2 and CXCR2/L1.2 transfected cells and on human PMNs. The efficacy of Reparixin is significantly lower in L1.2 cells expressing Ile43Val CXCR1 mutant (IC50 values of 5.6 nM and 80 nM for CXCR1 wt and CXCR1 Ile43Val, respectively)[1]. Reparixin is a non-competitive allosteric inhibitor of IL-8 receptors with a 400-fold higher efficacy in inhibiting CXCR1 activity than CXCR2[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 266359-93-7
-
Appearance Solid
-
Molecular Weight 429.57
-
Formula C20H35N3O5S
-
Color Off-white to light yellow
-
SMILES
N[C@@H](CCCCN)C(O)=O.CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O
-
Synonyms
Repertaxin L-lysine salt
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (63)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
2023 Apr 10;41(4):693-710.e8. PMID: 36963400 -
Science
2026 Mar 26;391(6792):eadz9353. PMID: 41538410 -
Ann Rheum Dis
Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. [Abstract]2016 Apr;75(4):721-9. PMID: 26612338 -
Ann Rheum Dis
Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. [Abstract]2016 Apr;75(4):730-8. PMID: 26613766 -
Nat Commun
Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. [Abstract]2017 May 26:8:15584. PMID: 28548090 -
J Biomed Sci
Fusobacterium nucleatum promotes colorectal cancer liver metastasis via miR-5692a/IL-8 axis by inducing epithelial-mesenchymal transition. [Abstract]2025 Jan 6;32(1):5. PMID: 39757156 -
Adv Sci (Weinh)
Single-Cell Landscape of Bronchoalveolar Lavage Fluid Identifies Specific Neutrophils during Septic Immunosuppression. [Abstract]2025 Mar;12(11):e2406218. PMID: 39887584 -
Adv Sci (Weinh)
SKAP1 Expression in Cancer Cells Enhances Colon Tumor Growth and Impairs Cytotoxic Immunity by Promoting Neutrophil Extracellular Trap Formation via the NFATc1/CXCL8 Axis. [Abstract]2024 Sep 13:e2403430. PMID: 39269257 -
Sci Adv
Differentiated fibrocytes assume a functional mesenchymal phenotype with regenerative potential. [Abstract]2019 May 8;5(5):eaav7384. PMID: 31086819 -
Mol Biomed
C-X-C motif chemokine ligand 1 derived from oral squamous cell carcinoma promotes cancer-associated fibroblast differentiation and tumor growth. [Abstract]2025 Jun 10;6(1):40. PMID: 40490643 -
Cell Death Dis
An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. [Abstract]2017 Jul 13;8(7):e2932. PMID: 28703802 -
Cancer Lett
DysUFMylation reprograms immunosuppressive neutrophils to potentiate anti-PD-1 therapy in hepatocellular carcinoma. [Abstract]2026 May 1:645:218395. PMID: 41780840 -
J Allergy Clin Immunol
Human TH17 cell development requires processing of dendritic cell-derived CXCL8 by neutrophil elastase. [Abstract]2018 Jun;141(6):2286-2289.e5. PMID: 29391256 -
Cell Commun Signal
Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells. [Abstract]2023 Mar 13;21(1):59. PMID: 36915147 -
Mol Ther
Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. [Abstract]2022 Nov 2;30(11):3430-3449. PMID: 35841152 -
EBioMedicine
Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model. [Abstract]2019 May:43:487-500. PMID: 31047862 -
Dev Cell
MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression. [Abstract]2026 Jan 12:S1534-5807(25)00768-3. PMID: 41529690 -
BMC Med
Upregulation of NOD1 and NOD2 contribute to cancer progression through the positive regulation of tumorigenicity and metastasis in human squamous cervical cancer. [Abstract]2022 Feb 8;20(1):55. PMID: 35130902 -
Cell Mol Gastroenterol Hepatol
Concomitant NAFLD Facilitates Liver Metastases and PD-1-Refractory by Recruiting MDSCs via CXCL5/CXCR2 in Colorectal Cancer. [Abstract]2024;18(2):101351. PMID: 38724007 -
Front Immunol
CXCR1 and its downstream NF-κB inflammation signaling pathway as a key target of Guanxinning injection for myocardial ischemia/reperfusion injury. [Abstract]2022 Oct 17:13:1007341. PMID: 36325326
Reparixin L-lysine salt purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Oct 17:13:1007341. [Abstract]
In HL-1 cells, when DSS and Reparixin (100nM) are applied in combination, the high expression levels of NF-κB, COX-2, ICAM-1 and VCAM-1 induced by OGD/R are further inhibited compared with that of DSS alone.
-
Cancer Cell Int
SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. [Abstract]2021 Jul 3;21(1):337. PMID: 34217295 -
Front Immunol
CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. [Abstract]2021 May 7:12:667177. PMID: 34025668 -
Front Immunol
Amphibian ( Xenopus laevis) Interleukin-8 (CXCL8): A Perspective on the Evolutionary Divergence of Granulocyte Chemotaxis. [Abstract]2018 Sep 12:9:2058. PMID: 30258441 -
Cell Biosci
1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation. [Abstract]2019 Jan 3:9:4. PMID: 30622698 -
Int Endod J
The Interplay of M1 Macrophages and Dental Pulp Stem Cells Promotes Angiogenesis Through IL-8-Dependent VEGF Regulation: An In Vitro Study. [Abstract]2026 Jun 24. PMID: 42339579 -
Cells
2026 Feb 3;15(3):289. PMID: 41677651 -
J Mol Cell Biol
CSF2 upregulates CXCL3 expression in adipocytes to promote metastasis of breast cancer via the FAK signaling pathway. [Abstract]2023 Aug 3;15(4):mjad025. PMID: 37073091 -
Cells
The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells. [Abstract]2022 Aug 4;11(15):2402. PMID: 35954247 -
Cells
2022 Jun 21;11(13):1986. PMID: 35805071 -
Neurobiol Dis
CXCR2 increases in ALS cortical neurons and its inhibition prevents motor neuron degeneration in vitro and improves neuromuscular function in SOD1G93A mice. [Abstract]2021 Dec:160:105538. PMID: 34743985 -
Oncogenesis
Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer. [Abstract]2016 Jun 13;5(6):e234. PMID: 27294866
Reparixin L-lysine salt purchased from MedChemExpress. Usage Cited in: Oncogenesis. 2016 Jun 13;5(6):e234. [Abstract]
The effects of Reparixin (100 nM) on the migration of OLFM4-depleted gastric cancer cells are detected by transwell assay.
-
Brain Pathol
Intracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells. [Abstract]2025 Jan;35(1):e13283. PMID: 38946128 -
J Mol Med (Berl)
Propionibacterium acnes induces discogenic low back pain via stimulating nucleus pulposus cells to secrete pro-algesic factor of IL-8/CINC-1 through TLR2-NF-κB p65 pathway. [Abstract]2019 Jan;97(1):25-35. PMID: 30397790 -
Biochim Biophys Acta Mol Basis Dis
The matrikine N-acetylated proline-glycine-proline induces premature senescence of nucleus pulposus cells via CXCR1-dependent ROS accumulation and DNA damage and reinforces the destructive effect of these cells on homeostasis of intervertebral discs. [Abstract]2017 Jan;1863(1):220-230. PMID: 27769935 -
Sci Rep
Protein profiling identified key chemokines that regulate the maintenance of human pluripotent stem cells. [Abstract]2017 Nov 6;7(1):14510. PMID: 29109449 -
Cancers (Basel)
Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8. [Abstract]2023 Sep 4;15(17):4422. PMID: 37686698 -
Stem Cells
Collagen-Derived N-Acetylated Proline-Glycine-Proline in Intervertebral Discs Modulates CXCR1/2 Expression and Activation in Cartilage Endplate Stem Cells to Induce Migration and Differentiation Toward a Pro-Inflammatory Phenotype. [Abstract]2015 Dec;33(12):3558-68. PMID: 26302999 -
J Cell Mol Med
Neuropilin-1 is up-regulated by cancer-associated fibroblast-secreted IL-8 and associated with cell proliferation of gallbladder cancer. [Abstract]2020 Nov;24(21):12608-12618. PMID: 32951327 -
J Cell Mol Med
IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. [Abstract]2020 Jan;24(2):1588-1598. PMID: 31793192 -
Brain Res Bull
Multi-omics analysis reveals the protective role of transcriptional enhancer factor and the pathogenic mechanism of monocytes in Parkinson's disease. [Abstract]2025 Nov:232:111594. PMID: 41135742 -
J Immunol
2018 Jul 15;201(2):814-820. PMID: 29802127 -
Xenotransplantation
Interleukin-8 mediates neutrophil-endothelial interactions in pig-to-human xenogeneic models. [Abstract]2018 Mar;25(2):e12385. PMID: 29427404 -
Mol Immunol
Interleukin 8 (CXCL8)-CXC chemokine receptor 2 (CXCR2) axis contributes to MiR-4437-associated recruitment of granulocytes and natural killer cells in ischemic stroke. [Abstract]2018 Sep:101:440-449. PMID: 30096583 -
J Gastroenterol Hepatol
High expression of tumor necrosis factor receptor-associated factor 2 promotes tumor metastasis and is associated with unfavorable prognosis in gastric cancer. [Abstract]2018 Feb;33(2):431-442. PMID: 28482378
Reparixin L-lysine salt purchased from MedChemExpress. Usage Cited in: J Gastroenterol Hepatol. 2018 Feb;33(2):431-442. [Abstract]
The effects of TRAF2 overexpression with or without Reparixin (100 nM), or BAY 11-7082 (30 μM) on the migration and invasion of AGS cell are examined by transwell assay.
-
Biomed Res Int
Icariin Ameliorates Lower Back Pain in Rats via Suppressing the Secretion of Cytokine-Induced Neutrophil Chemoatractant-1. [Abstract]2020 Aug 5:2020:4670604. PMID: 32802846 -
-
Gene
Conserved structure and function of chemokine CXCL8 between Chinese tree shrews and humans. [Abstract]2018 Nov 30:677:149-162. PMID: 30012425 -
Vet Immunol Immunopathol
CC chemokine ligand 2 and CXC chemokine ligand 8 as neutrophil chemoattractant factors in canine idiopathic polyarthritis. [Abstract]2016 Dec:182:52-58. PMID: 27863550 -
bioRxiv
2025 Sep 3:2025.09.02.672566. PMID: 40950232 -
bioRxiv
Mast cells interact directly with colorectal cancer cells to promote epithelial-to-mesenchymal transition. [Abstract]2025 Mar 19:2025.03.19.644113. PMID: 40166179 -
-
bioRxiv
2024 Jun 6:2024.01.30.577927. PMID: 38352492 -
-
-
Int J Biol Sci
Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF/CXCLs positive feedback loop. [Abstract]2022 Jan 16;18(4):1363-1380. PMID: 35280694 -
-
bioRxiv
SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients. [Abstract]2020 Sep 12:2020.08.25.265561. PMID: 32935097 -
-
Oncotarget
2018 Aug 24;9(66):32556-32569. PMID: 30220965 -
Oncotarget
Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. [Abstract]2017 Jul 21;8(36):60210-60222. PMID: 28947965
Reparixin L-lysine salt purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 21;8(36):60210-60222. [Abstract]
Migration assay of MDA-MB-231 cells treated 0.1 uM of Reparixin in CM from fibroblasts or macrophages with TCM of MDA-MB-231 cells using the Oris Cell migration kit.
-
-
-
Solvent & Solubility
H2O : 100 mg/mL (232.79 mM; Need ultrasonic)
DMSO : 100 mg/mL (232.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 40 mg/mL (93.12 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
L1.2 Cell suspension (1.5-3×106 cells/mL) is incubated at 37°C for 15 min in the presence of vehicle or of Reparixin (1 nM-1 μM) and next seeded in triplicates in the upper compartment of the chemotactic chamber. Different agonists are seeded in the lower compartment of the chamber at the following concentrations: 1 nM CXCL8, 0.03 nM fMLP, 10 nM CXCL1, 2.5 nM CCL2, 30 nM C5a. The chemotactic chamber is incubated at 37°C in air with 5% CO2 for 45 min (human PMNs) or 2 h (monocytes). At the end of incubation, the filter is removed, fixed, and stained and five oil immersion fields at high magnification (100×) are counted for each migration well after sample coding. L1.2 migration is evaluated using 5 μm pore size Transwell filters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats and Dogs[3]
Male and female Sprague-Dawley CD (albino) rats and male Lister Hooded (partially pigmented) rats are used. Male and female beagle Dogs (age about 15 months, bodyweight range 8.3-9.4 kg at the time of dosing) are used. Rats and Dogs are dosed i.v. with repurified [14C]-Reparixin free acid and an equivalent quantity of L-lysine suitably radiodiluted with Reparixin L-lysine salt in a solution of sterile isotonic (0.9%, w/v) saline. Rats are dosed with a solution of total drug concentration 9 mg/mL at a dose volume of 5 mL/kg (30 mg free Reparixin /kg) by bolus injection into a caudal vein. Dogs are dosed with a solution of total drug concentration 100 mg/mL at a dose volume of 0.5 mL/kg (33 mg free Reparixin/kg) by bolus injection into a superficial forelimb vein.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002. [Content Brief]
[2]. Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54. [Content Brief]
[3]. Midgley I, et al. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40 [Content Brief]
[5]. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.3279 mL | 11.6395 mL | 23.2791 mL | 58.1977 mL |
| 5 mM | 0.4656 mL | 2.3279 mL | 4.6558 mL | 11.6395 mL | |
| 10 mM | 0.2328 mL | 1.1640 mL | 2.3279 mL | 5.8198 mL | |
| 15 mM | 0.1552 mL | 0.7760 mL | 1.5519 mL | 3.8798 mL | |
| 20 mM | 0.1164 mL | 0.5820 mL | 1.1640 mL | 2.9099 mL | |
| 25 mM | 0.0931 mL | 0.4656 mL | 0.9312 mL | 2.3279 mL | |
| 30 mM | 0.0776 mL | 0.3880 mL | 0.7760 mL | 1.9399 mL | |
| 40 mM | 0.0582 mL | 0.2910 mL | 0.5820 mL | 1.4549 mL | |
| 50 mM | 0.0466 mL | 0.2328 mL | 0.4656 mL | 1.1640 mL | |
| 60 mM | 0.0388 mL | 0.1940 mL | 0.3880 mL | 0.9700 mL | |
| 80 mM | 0.0291 mL | 0.1455 mL | 0.2910 mL | 0.7275 mL | |
| 100 mM | 0.0233 mL | 0.1164 mL | 0.2328 mL | 0.5820 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Reparixin L-lysine salt Related Classifications
HY-15252 Related Classifications
Powered by Bioz